Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05776108 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation
A Phase 1 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT05776108 is a Phase 1 study that has completed, run by ViiV Healthcare. The registered enrollment target is 24 participants.
The verdict
NCT05776108, a Phase 1 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will assess the relative bioavailability of the CAB DT formulation relative to that of the CAB IR formulation and to assess the effect of food on the CAB DT formulation.
Interventions
- DRUG Cabotegravir IR Formulation (reference)
- DRUG Cabotegravir DT Formulation (test 1)
- DRUG Cabotegravir DT Formulation (test 2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-03-23 |
| Est. Completion | 2023-06-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05776108
The ClinicalTrials.gov registry entry for NCT05776108 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cabotegravir IR Formulation (reference) is the first listed.
NCT05776108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05776108 about?
NCT05776108 is a clinical study titled "A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation". This study will assess the relative bioavailability of the CAB DT formulation relative to that of the CAB IR formulation and to assess the effect of food on the CAB DT formulation.
What is the current status of trial NCT05776108?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2023-03-23. Estimated completion is 2023-06-08.
What interventions are being tested in trial NCT05776108?
The interventions under investigation include: Cabotegravir IR Formulation (reference) (DRUG), Cabotegravir DT Formulation (test 1) (DRUG), Cabotegravir DT Formulation (test 2) (DRUG).
Who is sponsoring clinical trial NCT05776108?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.